Quantum News
Sign InSign Up
Back to News
research

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Immunovant’s CEO Benjamin Zimmer and Roivant’s CEO Matthew Gline presented updates on two key drug programs during an April 2026 investor call, focusing on clinical expansions and Phase III trial results. Brepocitinib, a TYK2/JAK1 inhibitor, will expand into new autoimmune indications following positive interim data, targeting unmet needs in dermatomyositis and lupus nephritis. Batoclimab’s Phase III trial met primary endpoints in generalized myasthenia gravis, demonstrating statistically significant improvements in symptom control versus placebo. Regulatory submissions for batoclimab are planned by late 2026, with potential accelerated approval pathways being explored in the U.S. and EU. Analysts from firms like Leerink Partners and Goldman Sachs participated, probing commercialization timelines and market potential during the Q&A session.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (15).png
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts159.19K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update April 2, 2026 8:00 AM EDT Company Participants Benjamin Zimmer - President of Health Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd.Matthew Gline - Roivant Sciences Ltd.David Risinger - Leerink Partners LLC, Research DivisionLiam Hiester - Piper Sandler & Co., Research DivisionKatherine Kaiser-Dellorusso - LifeSci Capital, LLC, Research DivisionLut Ming Cheng - JPMorgan Chase & Co, Research DivisionWilliam Pickering - Bernstein Institutional Services LLC, Research DivisionSamantha Semenkow - Citigroup Inc., Research DivisionThomas Smith - Leerink Partners LLC, Research DivisionAnthea Li - Jefferies LLC, Research DivisionTchun-lim Wong - Goldman Sachs Group, Inc., Research DivisionAlexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research DivisionDouglas Tsao - H.C. Wainwright & Co, LLC, Research DivisionDina Ramadane - BofA Securities, Research DivisionChi Meng Fong - BofA Securities, Research Division Presentation Operator Good day, and welcome to the Brepocitinib Program Expansion and Batoclimab update. [Operator Instructions] Please note, this call is being recorded. I would now like to turn the call over to Stephanie Lee. Please go ahead.

Stephanie Lee GriffinRoivant Sciences Ltd. Good morning, and thanks for joining today's call to review Brepocitinib Program Expansion and an Update on Batoclimab. I'm Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant, and Ben Zimmer, CEO of Priovant. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. I'd like to remind you that we'll be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we filed with the SEC for more information

Read Original

Tags

quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.